Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Trial Evaluating αDC1 Vaccines Combined With Tumor-Selective Chemokine Modulation as Adjuvant Therapy After Surgical Resection of Peritoneal Surface Malignancies

Trial Profile

A Phase 1/2 Trial Evaluating αDC1 Vaccines Combined With Tumor-Selective Chemokine Modulation as Adjuvant Therapy After Surgical Resection of Peritoneal Surface Malignancies

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib (Primary) ; Dendritic cell vaccines (Primary) ; Interferon alpha-2b (Primary) ; Rintatolimod (Primary)
  • Indications Adenocarcinoma; Appendiceal cancer; Carcinoma; Colon cancer; Colorectal cancer; Mesothelioma; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Jul 2021 Status changed from no longer recruiting to discontinued as per results published in the Annals of Surgical Oncology
    • 09 Jul 2021 Results (N=46) of an evaluable data analysis published in the Annals of Surgical Oncology
    • 26 Dec 2018 Planned End Date changed from 1 Dec 2018 to 18 Feb 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top